Compare Illumina, Inc. (ILMN) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Levi Strauss & Co. — how do they compare? Illumina, Inc. trades at $191 (market cap $29.12B), while Levi Strauss & Co. trades at $22.63 (market cap $8.75B). The key difference: Illumina, Inc. is far larger — about 3.3× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays a 2.81% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | LEVI | |
|---|---|---|
Market Cap | $29.12B | $8.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $205.10 | $25.53 |
52-Week Low | $91.00 | $17.92 |
Enterprise Value | $30.48B | $10.07B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
Levi Strauss & Co. (LEVI) trades at $23.59, down 3.32% over 24 hours, amid a recent cybersecurity incident disclosed on August 7, 2026. The stock shows strong fundamentals with a P/E of 16.24, robust gross margin of 61.72%, and consistent earnings beats in recent quarters. Technical indicators are bearish, with support near $23, while analyst consensus remains bullish with a $27.88 price target.
The outlook for LEVI is positive due to solid DTC growth and raised 2026 guidance, but risks include cybersecurity concerns and tariff pressures. Earnings momentum and a reasonable valuation support upside potential, though near-term volatility may persist from the security breach and market reactions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
